miRNA-29 targets multiple profibrotic molecules and is down-regulated during fibrosis, including IPF. Previously, we showed a synthetic, chemically stabilized oligonucleotide mimic of miR-29b could repress collagen expression and abrogate pulmonary fibrosis in the bleomycin mouse model when administered I.V. Preliminary studies using a Scireq inExpose inhalation system yielded positive results with miR-29 mimic in bleomycintreated mice. Here, we sought to determine the feasibility of nebulizing miR-29 mimic (MRG-201) and to assess the distribution properties via nose-only inhalation in rats using a more sophisticated system. miR-29 mimic aerosols were generated with an Aeroneb Solo nebulizer, analyzed by HPLC for compound integrity, and connected to a nose-only rat inhalation system. Rats were challenged with bleomycin at day 0 and received a single dose of miR-29 mimic at target doses of 0.5 or 5 mg/kg by nose-only inhalation and were sacrificed 6, 24, or 48 hours later for analysis. Using a dual probe hybridization assay, distribution to the lung was robust and dose-dependent, with significant clearance at 48 hours. Minimal compound was detected in the kidney (4.9 pmol/g) and plasma (46 pmol/mL) at 6 hours in the 5 mg/kg group only, with no detection observed in heart, liver, or spleen. We then looked at target regulation following multiple administrations at two different doses. Daily administration of 1.0 mg/kg demonstrated significantly better target regulation than 0.1 mg/kg. These data demonstrate the feasibility of nebulizing and delivering a mimic of miR-29 by nose-only inhalation, with robust and restricted delivery to the lung. Methods 9-12 week old female mice received 10 or 25 mg/kg via aerosol (Scireq) 10 days after bleomycin treatment. We used 10 mice per group and the mice were sacrificed at day 21. Lung and BAL were harvested for histopathology and molecular analysis of fibrotic markers and drug delivery. For all experiments we used oligonucleotides synthesized at miRagen Therapeutics, Inc. For rat inhalation studies, all studies were performed at Lovelace Respiratory Research Institute. miR-29 mimic aerosols were generated with an Aeroneb Solo nebulizer, analyzed by HPLC for compound integrity, and connected to a nose-only rat inhalation system. Male rats were challenged with bleomycin at day 0 and received a single dose of miR-29 mimic at target doses of 0.5 or 5 mg/kg by nose-only inhalation and were sacrificed 6, 24, or 48 hours later for analysis. Plasma, lung, liver, kidney, spleen, and heart were collected for distribution analyses. For multi-day treatments, (n=5/group) rats were challenged at day 0 with bleomycin, and received 0.1 mg/kg/day or 1.0 mg/kg/day for 5 consecutive days starting at day 2. Rats were sacrificed at day 7, lung and plasma collected for target engagement and compound detection. 
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Biodistribution of miR-29 mimic
▪ Biodistribution analyses show robust and relatively dose-dependent exposure to the lung with significant clearance at 48 hours ▪ For heart, liver, and spleen, the average (or median) values were BLOQ. ▪ For kidney, there was very low levels detected at 6 hrs only for the 5 mg/kg, about 2x above the LLOQ (2.5 pmol/g; 42.7 ng/g). ▪ Plasma levels were only detectable at the 5 mg/kg dose 6 hours post dosing (46±24 pmol/mL); all other time points for both dose levels were BLOQ.
day 2 day 6 day 0 day 7 ( Expression of miR-29 and fibrotic targets in lung after miR-29 mimic administration. Stress markers are increased with bleomycin at day 7 (A). miR-29 mimic and pirfenidone reduce expression of stress markers (B).
▪ miR-29 mimics can be nebulized and administered via nose-only inhalation to mice and rats.
▪ Distribution to tissues beyond the lung is very minimal, with only small detection in the kidney six hours after administration of the highest dose.
▪ Following multiple administrations, aerosolized miR-29 mimics at 1.0mg/kg can downregulate target genes induced by bleomycin in rats.
A. B.
